DE69520282T2 - Pyrrolo[2,3-d]pyrimidinderivate und ihre verwendung - Google Patents

Pyrrolo[2,3-d]pyrimidinderivate und ihre verwendung

Info

Publication number
DE69520282T2
DE69520282T2 DE69520282T DE69520282T DE69520282T2 DE 69520282 T2 DE69520282 T2 DE 69520282T2 DE 69520282 T DE69520282 T DE 69520282T DE 69520282 T DE69520282 T DE 69520282T DE 69520282 T2 DE69520282 T2 DE 69520282T2
Authority
DE
Germany
Prior art keywords
compounds
alkyl
pct
trifluoromethyl
unsubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69520282T
Other languages
English (en)
Other versions
DE69520282D1 (de
Inventor
Martin Missbach
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Pharma GmbH
Novartis AG
Original Assignee
Novartis Erfindungen Verwaltungs GmbH
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Erfindungen Verwaltungs GmbH, Novartis AG filed Critical Novartis Erfindungen Verwaltungs GmbH
Application granted granted Critical
Publication of DE69520282D1 publication Critical patent/DE69520282D1/de
Publication of DE69520282T2 publication Critical patent/DE69520282T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
DE69520282T 1994-09-29 1995-09-08 Pyrrolo[2,3-d]pyrimidinderivate und ihre verwendung Expired - Lifetime DE69520282T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH295394 1994-09-29
PCT/EP1995/003536 WO1996010028A1 (en) 1994-09-29 1995-09-08 PYRROLO[2,3-d]PYRIMIDINES AND THEIR USE

Publications (2)

Publication Number Publication Date
DE69520282D1 DE69520282D1 (de) 2001-04-12
DE69520282T2 true DE69520282T2 (de) 2001-08-09

Family

ID=4245363

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69520282T Expired - Lifetime DE69520282T2 (de) 1994-09-29 1995-09-08 Pyrrolo[2,3-d]pyrimidinderivate und ihre verwendung

Country Status (20)

Country Link
US (1) US5869485A (de)
EP (1) EP0783505B1 (de)
JP (1) JP4145955B2 (de)
KR (1) KR970706288A (de)
CN (1) CN1046731C (de)
AT (1) ATE199553T1 (de)
AU (1) AU694801B2 (de)
BR (1) BR9509048A (de)
CA (1) CA2200210A1 (de)
DE (1) DE69520282T2 (de)
DK (1) DK0783505T3 (de)
ES (1) ES2157344T3 (de)
FI (1) FI112867B (de)
GR (1) GR3035996T3 (de)
HU (1) HU222181B1 (de)
MX (1) MX9702307A (de)
NO (1) NO308108B1 (de)
NZ (1) NZ293249A (de)
PT (1) PT783505E (de)
WO (1) WO1996010028A1 (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0682027T3 (da) * 1994-05-03 1998-05-04 Ciba Geigy Ag Pyrrolopyrimidinderivater med antiproliferativ virkning
MX9800215A (es) * 1995-07-06 1998-03-31 Novartis Ag Pirrolopirimidas y procesos para su preparacion.
AU3176297A (en) * 1996-06-25 1998-01-14 Novartis Ag Substituted 7-amino-pyrrolo{3,2-d}pyrimidines and the use thereof
EP0912562A1 (de) * 1996-07-19 1999-05-06 Takeda Chemical Industries, Ltd. Heterocyclische verbindungen, ihre herstellung und verwendung
JP4056589B2 (ja) * 1996-07-19 2008-03-05 武田薬品工業株式会社 複素環化合物、その製造法および用途
ATE384062T1 (de) 1996-08-23 2008-02-15 Novartis Pharma Gmbh Substituierte pyrrolopyrimidine und verfahren zu ihrer herstellung
WO1998014450A1 (en) 1996-10-02 1998-04-09 Novartis Ag Pyrimidine derivatives and processes for the preparation thereof
GB9704948D0 (en) 1997-03-11 1997-04-30 Knoll Ag Therapeutic agents
ID24653A (id) * 1997-03-19 2000-07-27 Basf Ag Zat-zat terapi
US7863444B2 (en) 1997-03-19 2011-01-04 Abbott Laboratories 4-aminopyrrolopyrimidines as kinase inhibitors
JP3711238B2 (ja) * 1997-08-05 2005-11-02 ファイザー・プロダクツ・インク 神経ペプチドＹ受容体アンタゴニストとしての４−アミノピロ−ル（３，２−ｄ）ピリミジン
MXPA00011889A (es) * 1998-06-02 2003-04-25 Osi Pharm Inc Composiciones de pirrolo (2,3d) piridina y su uso.
JP2002526500A (ja) * 1998-09-18 2002-08-20 ビーエーエスエフ アクチェンゲゼルシャフト プロテインキナーゼ阻害剤としてのピロロピリミジン
US6713474B2 (en) 1998-09-18 2004-03-30 Abbott Gmbh & Co. Kg Pyrrolopyrimidines as therapeutic agents
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
SK3812002A3 (en) 1999-09-17 2003-09-11 Abbott Gmbh & Co Kg Pyrazolopyrimidines as therapeutic agents
US7071199B1 (en) 1999-09-17 2006-07-04 Abbott Gmbh & Cco. Kg Kinase inhibitors as therapeutic agents
AU2000240570A1 (en) * 2000-03-29 2001-10-08 Knoll Gesellschaft Mit Beschraenkter Haftung Pyrrolopyrimidines as tyrosine kinase inhibitors
JP2005502643A (ja) * 2001-08-10 2005-01-27 ノバルティス　アクチエンゲゼルシャフト 白血病処置のための単独またはｓｔｉ５７１と組み合せたｃ−ｓｒｃインヒビターの使用
US6770652B2 (en) * 2001-10-18 2004-08-03 Duquesne University Of The Holy Ghost Multiple acting anti-angiogenic and cytotoxic compounds and methods for using the same
DE10163991A1 (de) * 2001-12-24 2003-07-03 Merck Patent Gmbh Pyrrolo-pyrimidine
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
GB0226370D0 (en) * 2002-11-12 2002-12-18 Novartis Ag Organic compounds
US7157460B2 (en) * 2003-02-20 2007-01-02 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
JP2007520559A (ja) * 2004-02-03 2007-07-26 アボット・ラボラトリーズ 治療薬としてのアミノベンゾオキサゾール類
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
EP2385053B1 (de) * 2005-11-17 2013-10-02 OSI Pharmaceuticals, Inc. Zwischenprodukte für die Herstellung von kondensierten bicyclischen mTOR-Inhibitoren
ES2545907T3 (es) * 2005-12-29 2015-09-16 Abbvie Inc. Inhibidores de proteína quinasa
EP1981890A2 (de) * 2006-01-25 2008-10-22 OSI Pharmaceuticals, Inc. UNGESÄTTIGTE mTOR-HEMMER
KR20110017845A (ko) * 2008-03-19 2011-02-22 오에스아이 파마슈티컬스, 인코포레이티드 Ｍｔｏｒ 억제자 염 형태
ES2570429T3 (es) * 2008-10-16 2016-05-18 Univ California Inhibidores de heteroaril quinasa de anillo condensado
WO2010066629A2 (en) * 2008-12-09 2010-06-17 F. Hoffmann-La Roche Ag Novel azaindoles
BR112012005400A2 (pt) 2009-09-10 2016-04-05 Irm Llc derivados do tipo éter de heteroarilas bicíclicas
JP2013512215A (ja) 2009-11-25 2013-04-11 ノバルティス アーゲー 二環式ヘテロアリールのベンゼン縮合６員酸素含有ヘテロ環誘導体
JP2013532149A (ja) 2010-06-17 2013-08-15 ノバルティス アーゲー ピペリジニル置換１，３−ジヒドロ−ベンゾイミダゾール−２−イリデンアミン誘導体
CN102947274A (zh) 2010-06-17 2013-02-27 诺瓦提斯公司 联苯基取代的1,3-二氢-苯并咪唑-2-亚基胺衍生物
JP2014507465A (ja) 2011-03-08 2014-03-27 ノバルティス アーゲー フルオロフェニル二環式ヘテロアリール化合物
AU2012225232B2 (en) 2011-03-09 2016-05-12 Richard G. Pestell Prostate cancer cell lines, gene signatures and uses thereof
CA2846496C (en) 2011-09-02 2020-07-14 The Regents Of The University Of California Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
CA2873743C (en) 2012-05-14 2022-12-06 Prostagene, Llc Using modulators of ccr5 for treating cancer
JP2015532287A (ja) 2012-09-26 2015-11-09 ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア Ｉｒｅ１の調節
WO2014145576A2 (en) 2013-03-15 2014-09-18 Northwestern University Substituted pyrrolo(2,3-d)pyrimidines for the treatment of cancer
EP3194572B1 (de) 2014-07-30 2023-10-25 Yeda Research and Development Co. Ltd. Medien zur kultivierung pluripotenter stammzellen
WO2017027883A1 (en) 2015-08-13 2017-02-16 San Diego State University Research Foundation Atropisomerism for increased kinase inhibitor selectivity
WO2017156350A1 (en) 2016-03-09 2017-09-14 K-Gen, Inc. Methods of cancer treatment
EP3730483B1 (de) 2017-12-21 2023-08-30 Hefei Institutes of Physical Science, Chinese Academy of Sciences Klasse von pyrimidinderivaten als kinaseinhibitoren
WO2020113094A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
WO2020152686A1 (en) 2019-01-23 2020-07-30 Yeda Research And Development Co. Ltd. Culture media for pluripotent stem cells
WO2021097256A1 (en) 2019-11-14 2021-05-20 Cohbar, Inc. Cxcr4 antagonist peptides

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9300059D0 (en) * 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
GB9314884D0 (en) * 1993-07-19 1993-09-01 Zeneca Ltd Tricyclic derivatives
IL112249A (en) * 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
DK0682027T3 (da) * 1994-05-03 1998-05-04 Ciba Geigy Ag Pyrrolopyrimidinderivater med antiproliferativ virkning

Also Published As

Publication number Publication date
CN1046731C (zh) 1999-11-24
NO971342L (no) 1997-03-21
HU222181B1 (hu) 2003-04-28
ATE199553T1 (de) 2001-03-15
NO308108B1 (no) 2000-07-24
AU3564395A (en) 1996-04-19
JPH10506624A (ja) 1998-06-30
FI112867B (fi) 2004-01-30
FI971225A (fi) 1997-05-14
EP0783505B1 (de) 2001-03-07
HUT76785A (en) 1997-11-28
DK0783505T3 (da) 2001-07-02
DE69520282D1 (de) 2001-04-12
NZ293249A (en) 1999-04-29
ES2157344T3 (es) 2001-08-16
CA2200210A1 (en) 1996-04-04
US5869485A (en) 1999-02-09
AU694801B2 (en) 1998-07-30
JP4145955B2 (ja) 2008-09-03
MX9702307A (es) 1998-04-30
CN1164234A (zh) 1997-11-05
FI971225A0 (fi) 1997-03-24
KR970706288A (ko) 1997-11-03
NO971342D0 (no) 1997-03-21
PT783505E (pt) 2001-08-30
WO1996010028A1 (en) 1996-04-04
BR9509048A (pt) 1998-01-06
EP0783505A1 (de) 1997-07-16
GR3035996T3 (en) 2001-09-28

Similar Documents

Publication Publication Date Title
DE69520282D1 (de) Pyrrolo[2,3-d]pyrimidinderivate und ihre verwendung
DE59710417D1 (de) N-7 HETEROCYCLYL-PYRROLO[ 2,3-d]PYRIMIDINE UND IHRE VERWENDUNG
AP2002002643A0 (en) 5-alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors
CY1105618T1 (el) Δικυκλικες ετεροαρωματικες ενωσεις ως αναστολεις της κινασης τυροσινης πρωτεϊνης
EA200200473A1 (ru) Ингибиторы тирозинкиназы
DK0938486T3 (da) Substituerede pyrrolopyrimidiner og fremgangsmåder til deres fremstilling
MY134848A (en) Pyrrolo[2,1-f] [1,2,4] triazine inhibitors of kinases
ES2193362T3 (es) Derivados de 2-pirimidinamina y su procedimiento de preparacion de los mismos.
CY1107509T1 (el) Αμινοθειαζολες ως αναστολεις κυκλινη - εξαρτωμενων κινασεων
HUP0004807A2 (hu) Vérlemezkéből származó növekedési faktort és/vagy P56lck tirozin kinázokat gátló hatású kinolin- és kinoxalin-vegyületek, alkalmazásuk gyógyászati készítmények előállítására és a vegyületeket tartalmazó gyógyászati készítmények
NO975956L (no) Pyrrolopyrimidiner og fremgangsmåter for deres fremstilling
PT880507E (pt) Derivados de quinazolina como agentes anti-tumorais
TR199900048T2 (xx) Protein tirozin kinaz inhibit�rleri olarak bisiklik heteroaromatik bile�ikler
EA199900022A1 (ru) Бициклические гетероароматические соединения в качестве ингибиторов протеинтирозинкиназы
EA200000842A1 (ru) Бицикло [2.2.1] гептаны и родственные соединения
AR006906A1 (es) Derivados de indazol sustituidos, composiciones farmaceuticas que los contienen, uso de los mismos e intermediarios de sintesis
UA87895C2 (en) Substituted 5-phenyl pyrimidines i in therapy
ATE150751T1 (de) Neuroprotektive 3,4-dihydro-2(1h)-chinolone
DK0526588T3 (da) Heterocykliske forbindelser, deres fremstilling og anvendelse
MXPA05010975A (es) Derivados de (6-(fenoxi)-pirido[3,4-d]pirimidin-2-il)-amina como inhibidores de p38 cinasa para el tratamiento de condiciones inflamatorias como artritis reumatoide.
UY26866A1 (es) Proceso para preparar 2-(4-piridil) amino-6-dialquiloxifenilpirido (2,3-d) pirimidin-7-onas
ATE193705T1 (de) 4-p-fluorbenzoyl-1-piperidinyl-propoxy-chromen- - on derivate, deren herstellung und deren verwendung zur behandlung von psychosen und schizophrenie
ES2193047T3 (es) (3,4 dihydro-2h-benzo(1,4) oxazinilmetil)(3-(1h-indol-3-il)-alquil)-aminas.
FR2543139B1 (fr) Derives de (1-alcoxy 2-amino) ethyl pyridine ou pyrazine, leur preparation et leur application en therapeutique
EA200400560A1 (ru) ПРОИЗВОДНЫЕ 3-ГЕТЕРОАРИЛ-3,5-ДИГИДРО-4-ОКСО-4H-ПИРИДАЗИНО[4,5-b]ИНДОЛ-1-КАРБОКСАМИДА, ИХ ПОЛУЧЕНИЕ И ТЕРАПЕВТИЧЕСКОЕ ПРИМЕНЕНИЕ

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336

8328 Change in the person/name/address of the agent

Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN